Bristol Myers Squibb tested Cobenfy as an adjunctive treatment with atypical antipsychotics for schizophrenia in the Phase ...

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

MapLight Therapeutics has raised a $372.5 million series D round, clearing the biotech to chart a course through phase 2 for ...

Q2 2025 Earnings Call Transcript July 31, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is $1.46, expectations were $1.07. Operator: Good day, and welcome to the ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

Q2 2025 Management View CEO Christopher S. Boerner highlighted, "Our growth portfolio delivered another strong quarter with sales increasing 17% year-over-year, primarily driven by demand across all ...

Bristol Myers Squibb reported unexpectedly strong second-quarter results, driven by legacy products like Eliquis, despite ...

Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...

BMS set a $1,850 per month wholesale price for Cobenfy, or more than $22,000 per year, which is in line with other brand name antipsychotics. Competition is coming from other muscarinic receptor ...

How Is Cobenfy Supplied and How Do I Take It? Cobenfy is an oral capsule that is taken twice daily for schizophrenia. Cobenfy is available in three strengths of capsules, each of which comes in a ...